查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423077

2024-2032 年按治疗领域、药物传输、配销通路和国家分類的仿製药市场报告

Generic Drugs Market Report by Therapy Area, Drug Delivery, Distribution Channel, and Country 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年全球仿製药市场规模达3,671亿美元。展望未来， IMARC Group预计到2032年市场规模将达到6,280亿美元，2024-2032年复合年增长率（CAGR）为5.96%。各种慢性疾病的日益普及、製药业研究相关活动的投资增加以及品牌药物专利到期的数量增加是推动市场的一些主要因素。

仿製药是指在活性成分、剂型、规格、给药途径、品质、安全性和功效方面与品牌药生物等效的药物。它们由多种药物组成，包括布洛芬、二甲双胍和辛伐他汀。它们是在原厂药的专利保护到期后生产的。它们已获得监管机构的批准，并且价格实惠。它们在管理各种健康状况（如高血压、糖尿病、感染和心血管疾病）方面发挥着至关重要的作用。它们对于提高负担能力至关重要，特别是对于没有全面保险或面临高额费用的个人而言。

由于品牌药专利到期数量的增加，对仿製药的需求不断增加，推动了市场的成长。除此之外，全球医疗保健服务成本的不断增长也提供了有利的市场前景。此外，全球患有心血管疾病、糖尿病和呼吸系统疾病等各种慢性疾病的老年人口不断增加，也促进了市场的成长。除此之外，主要市场参与者之间为增加各种仿製药产量而进行的合作数量不断增加，正在支持市场的成长。此外，製药业越来越多地整合技术先进的设备来生产具有特殊配方的各种复杂的仿製药，这也促进了市场的成长。

仿製药市场趋势/驱动因素：

慢性病盛行率上升

目前，由于不健康的生活习惯日益盛行，群众慢性病盛行率上升。久坐的生活方式和不良饮食（加工食品和快餐的消费增加）是导致糖尿病、心臟病和某些癌症等慢性疾病增加的重要因素。除此之外，过量饮酒和吸烟也导致各种慢性疾病的发生，例如高血压和心血管併发症。此外，慢性压力通常是现代快节奏生活方式的副产品，可能会导致一系列健康问题，包括心臟病和精神疾病。然而，增强的筛检和诊断工具可以更好、更早、更频繁地检测慢性病。此外，各种仿製药的消费正在帮助患者治疗多种慢性疾病。

製药业不断成长的研究相关活动

目前，製药业为开发新疾病的治疗方法和疫苗而进行的研究活动增加。除此之外，随着世界各地老年人口的增加，对药物的需求也增加。此外，基因组学、蛋白质组学和生物资讯学等领域的最新突破正在为药物发现和开发开闢新途径。在分子层面上操纵基因和蛋白质的能力，以及对分子和基因层面上疾病机制的日益了解，正在为标靶治疗的发展铺平道路。除此之外，製药公司正在投资生产各种品牌药物的仿製药，以使患者负担得起且易于获得。

越来越多的政府措施提供负担得起的医疗保健服务

各国管理机构都在大力投资，使医疗服务变得负担得起，并寻找各种慢性病的治疗方法。他们也采取了许多倡议，包括补贴医疗费用、实施降低药物成本的政策、提供保险以及投资公共卫生设施和计画。除此之外，各国政府都致力于透过在农村地区建造免费诊所来缩小不同收入和社会群体之间的健康差距。这些诊所还优先以名目价格提供仿製药和各种其他药物，并提供免费检查。

仿製药市场趋势：

全球老年人口不断增长，癌症、糖尿病和心血管疾病等慢性疾病的发生率不断上升，是积极影响市场的关键因素之一。此外，饮食模式的改变和个人忙碌的日程安排导致了各种状况，这反过来又刺激了全球对仿製药的需求。同时，各国政府加强努力降低医疗成本并促进仿製药的生产和使用，也促进了市场的成长。他们还鼓励主要参与者推出有效的仿製药并提供容易取得的药物。除此之外，仿製药的低生产成本正在为市场创造积极的前景。此外，製药公司和医疗商店在全球范围内的扩张进一步促进了市场成长。此外，领先製造商日益关注推出新产品的合作伙伴策略，正在推动市场成长。此外，对广泛研发（R＆D）活动的​​投资增加以及药物配方的技术进步预计将推动市场发展。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球仿製药产业

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场细分：按国家/地区
  • 市场区隔：按治疗领域
  • 市场细分：按药物输送
  • 市场区隔：按配销通路
  • 市场预测
  • SWOT分析
    • 概述
    • 优势
    • 弱点
    • 机会
    • 威胁
  • 价值链分析
    • 研究与开发
    • 製造业
    • 行销与分销
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 非专利药产业的法规
  • 主要市场驱动因素与成功因素

第 6 章：主要国家的表现

  • 美国
    • 市场走向
    • 市场预测
  • 中国
    • 市场走向
    • 市场预测
  • 巴西
    • 市场走向
    • 市场预测
  • 德国
    • 市场走向
    • 市场预测
  • 法国
    • 市场走向
    • 市场预测
  • 印度
    • 市场走向
    • 市场预测
  • 英国
    • 市场走向
    • 市场预测
  • 日本
    • 市场走向
    • 市场预测
  • 加拿大
    • 市场走向
    • 市场预测
  • 义大利
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依治疗领域

  • 中枢神经系统
    • 市场走向
    • 市场预测
  • 心血管
    • 市场走向
    • 市场预测
  • 皮肤科
    • 市场走向
    • 市场预测
  • 泌尿生殖系统/荷尔蒙
    • 市场走向
    • 市场预测
  • 呼吸系统
    • 市场走向
    • 市场预测
  • 风湿病学
    • 市场走向
    • 市场预测
  • 糖尿病
    • 市场走向
    • 市场预测
  • 肿瘤学
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场细分：依药物输送

  • 口服
    • 市场走向
    • 市场预测
  • 注射剂
    • 市场走向
    • 市场预测
  • 皮肤/外用
    • 市场走向
    • 市场预测
  • 吸入器
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按配销通路

  • 零售药局
    • 市场走向
    • 市场预测
  • 医院药房
    • 市场走向
    • 市场预测

第 10 章：竞争格局

  • 市场结构
  • 市场区隔：按关键参与者
  • 主要球员简介
    • Teva Pharmaceuticals Industries Ltd.
    • Mylan NV
    • Novartis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Fresenius SE & Co.
    • Lupin Limited
    • Endo Pharmaceuticals Inc.
    • Aurobindo Pharma Limited
    • Aspen Pharmacare Holdings Limited

第 11 章：仿製药生产流程

  • 产品概述
  • 详细製程（片剂）
  • 详细製程（注射）
  • 涉及的各种类型的单元操作
  • 质量平衡和原料要求

第 12 章：专案细节、要求与涉及的成本

  • 土地需求和支出
  • 建设需求及支出
  • 工厂机械
  • 机械图片
  • 原料需求及支出
  • 包装要求及费用
  • 交通需求及支出
  • 公用事业要求和支出
  • 人手需求及开支
  • 其他资本投资

第 13 章：贷款与财务援助

第 14 章：专案经济学

  • 专案资本成本
  • 技术经济参数
  • 供应链各层面的产品定价与利润
  • 税金和折旧
  • 收入预测
  • 支出预测
  • 财务分析
  • 利润分析

图一览

表列表

简介目录
Product Code: SR112024A549

Abstract

The global generic drugs market size reached US$ 367.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 628.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.96% during 2024-2032. The growing prevalence of various chronic diseases, rising investments in research-related activities in the pharmaceutical industry, and increasing number of patent expirations of brand name drugs are some of the major factors propelling the market.

Generic drugs are medications that are bioequivalent to brand-name drugs in terms of active ingredients, dosage form, strength, route of administration, quality, safety, and efficacy. They consist of a wide range of medications, including ibuprofen, metformin, and simvastatin. They are produced after the patent protection of the brand-name drug expires. They are approved by regulatory authorities and available at affordable prices. They play a vital role in managing various health conditions, such as hypertension, diabetes, infections, and cardiovascular diseases. They are essential in improving affordability, particularly for individuals without comprehensive insurance coverage or facing high expenses.

The increasing demand for generic drugs due to the rising number of patent expirations of brand name drugs is impelling the growth of the market. Besides this, the growing cost of healthcare services around the world is offering a favorable market outlook. In addition, the increasing geriatric population across the globe experiencing various chronic conditions, such as cardiovascular diseases, diabetes, and respiratory disorders, is contributing to the growth of the market. Apart from this, the rising number of collaborations between key market players to increase the production of various generic drugs is supporting the growth of the market. Additionally, the increasing integration of technologically advanced equipment in the pharmaceutical industry to produce various complex generic drugs with specialized formulations is bolstering the growth of the market.

Generic Drugs Market Trends/Drivers:

Rising prevalence of chronic diseases

At present, there is an increase in the prevalence of chronic diseases among the masses due to the rising adoption of unhealthy lifestyle habits. Sedentary lifestyles and poor diet (increased consumption of processed and fast foods) are significant contributors to a rise of chronic ailments like diabetes, heart disease, and certain cancers. Apart from this, the excessive consumption of alcohol and tobacco is propelling the occurrence of various chronic disorders, such as hypertension and cardiovascular complications. In addition, chronic stress, often a byproduct of the modern, fast-paced lifestyle, can contribute to a host of health problems, including heart disease and mental illness. However, enhanced screening and diagnostic tools are leading to better, earlier, and more frequent detection of chronic conditions. Furthermore, the consumption of various generic drugs is helping patients to treat a wide array of chronic diseases.

Growing research-related activities in the pharmaceutical industry

At present, there is an increase in research activities in the pharmaceutical industry to develop treatments and vaccines for emerging diseases. Besides this, the demand for medications is increasing as the geriatric population is rising around the world. Moreover, recent breakthroughs in areas, such as genomics, proteomics, and bioinformatics, are opening new avenues for drug discovery and development. The ability to manipulate genes and proteins at a molecular level, and the increasing understanding of disease mechanisms at the molecular and genetic levels, are paving the way for the development of targeted therapies. Apart from this, pharmaceutical companies are investing in manufacturing various generic versions of branded drugs to make them affordable and easily accessible for patients.

Increasing number of government initiatives to provide affordable healthcare services

Governing agencies of various countries are heavily investing in making healthcare services affordable and finding treatments for various chronic illnesses. They are also taking numerous initiatives, including subsidizing healthcare costs, implementing policies to reduce the cost of drugs, providing insurance coverage, and investing in public health facilities and programs. Apart from this, governing authorities of various countries are focusing on reducing health disparities among different income and social groups by constructing free clinics in various rural areas. These clinics are also prioritizing generic drugs and various other medications for nominal prices, along with free checkups.

Generic Drugs Market Trends:

The growing global geriatric population and the rising occurrence of chronic medical disorders, such as cancer, diabetes, and cardiovascular diseases, represent one of the key factors positively influencing the market. In addition, changing dietary patterns and hectic schedules of individuals are leading to various conditions, which, in turn, is catalyzing the demand for generic drugs worldwide. Along with this, increasing efforts by governments of various countries to reduce healthcare costs and promote the manufacturing and uptake of generics are contributing to the market growth. They are also encouraging key players to introduce effective generic drugs and provide easy availability. Apart from this, the low production cost of generic medicines is creating a positive outlook for the market. Additionally, the expansion of the pharma companies and medical stores across the globe is further augmenting the market growth. Furthermore, the rising focus of leading manufacturers on partnership strategies to launch new products is propelling the market growth. Moreover, increasing investments in extensive research and development (R&D) activities and technological advancements in medicine formulation are anticipated to drive the market.

Generic Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global generic drugs market report, along with forecasts at the global and country levels from 2024-2032. Our report has categorized the market based on therapy area, drug delivery, and distribution channel.

Breakup by Therapy Area:

Central Nervous System

Cardiovascular

Dermatology

Genitourinary/Hormonal

Respiratory

Rheumatology

Diabetes

Oncology

Others

Central nervous system dominates the market

The report has provided a detailed breakup and analysis of the market based on the therapy area. This includes central nervous system, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, oncology, and others. According to the report, central nervous system represented the largest segment.

Generic drugs play a significant role in the treatment of various central nervous system (CNS) disorders. They offer several benefits, including affordability, accessibility, and comparable efficacy to their brand-name counterparts. They comprise serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline, and escitalopram, that are commonly prescribed for these conditions. They also consist of antiepileptic drugs, including levetiracetam, lamotrigine, and topiramate, which are commonly prescribed and have proven efficacy in controlling seizures. They are used to treat Parkinson's disease and attention deficit hyperactivity disorder (ADHD).

Generic drugs are employed for curing cardiovascular complications, such as hypertension or hypertension, coronary artery diseases, heart failure, and arrhythmias. They consist of diuretics, aldosterone antagonists, digoxin, beta-blockers, and calcium channel blockers.

Breakup by Drug Delivery:

Oral

Injectables

Dermal/Topical

Inhalers

Oral holds the largest share in the market

A detailed breakup and analysis of the market based on the drug delivery have also been provided in the report. This includes oral, injectables, dermal/topical, and inhalers. According to the report, oral accounted for the largest market share as they are generally easy to administer and can be self-administered by the patient. They can be taken at home or on the go without the need for medical supervision or assistance. Besides this, oral drugs can be obtained from pharmacies, hospitals, or prescribed by healthcare providers, making it convenient for patients to obtain and take their medications. They can be taken in a non-invasive manner by eliminating the need for needles, injections, or invasive procedures, which can be uncomfortable or cause anxiety for some individuals. They can get absorbed through the digestive system, allowing for efficient delivery into the bloodstream. Furthermore, oral medications offer a higher level of patient compliance as they are easy to consume regularly.

Breakup by Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Retail pharmacies account for the majority of the market share

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes retail pharmacies and hospital pharmacies. According to the report, retail pharmacies accounted for the largest market share.

Retail pharmacies, also known as community pharmacies or outpatient pharmacies, are establishments wherein prescription medications, over the counter (OTC) drugs, and other healthcare products are dispensed and sold directly to consumers. These pharmacies are commonly found in retail settings, such as drugstore chains, supermarkets, or independent pharmacies. They play a crucial role in providing accessible and convenient pharmaceutical services to the public. They present a wide variety of medications, including pain relievers, cough and cold medicines, allergy medications, and more. Besides this, they often stock various health and wellness products, such as supplements, vitamins, personal care items, first aid supplies, and medical devices like blood pressure monitors and glucose meters.

Breakup by Country:

United States

China

Brazil

Germany

France

India

United Kingdom

Japan

Canada

Italy

Others

The United States exhibits a clear dominance, accounting for the largest generic drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include the United States, China, Brazil, Germany, France, India, the United Kingdom, Japan, Canada, Italy, and others.

The United States held the biggest market share since the region has an advanced medical infrastructure and efficient regulatory support. Besides this, the increasing number of insurance companies and healthcare providers encouraging patients to consume generic drugs is propelling the growth of the market. Apart from this, increasing availability of generic drugs at affordable prices are bolstering the growth of the market. Moreover, the growing occurrence of various chronic diseases among the masses is influencing the market positively.

China is estimated to expand further in this domain due to the increasing investments in developing novel drugs and promoting the use of generic drugs. Besides this, the rising construction of hospitals, nursing homes, and clinics is propelling the growth of the market in the country.

Competitive Landscape:

Key market players are investing in research activities to develop a pipeline of generic drugs. They are also focusing on identifying opportunities to introduce generic versions of brand-name drugs as patents expire. Top companies are forming strategic partnerships or engaging in acquisitions to strengthen their market position and expand their capabilities. They are also collaborating with other generic drug manufacturers, contract research organizations (CROs), or acquiring smaller companies to achieve access to new markets or technologies. Leading companies are expanding their geographic reach by entering new market positions and establishing a presence in emerging economies. They are also focusing on the development of complex generic drugs, such as extended-release formulations, transdermal patches, inhalers, and injectables.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Teva Pharmaceuticals Industries Ltd.

Mylan N.V.

Novartis AG

Pfizer Inc.

Sun Pharmaceutical Industries Ltd.

Fresenius SE & Co.

Lupin Limited

Endo Pharmaceuticals Inc.

Aurobindo Pharma Limited

Aspen Pharmacare Holdings Limited

Recent Developments:

In May 2023, Teva Pharmaceuticals Industries Ltd. announced that it will present data demonstrating UZEDY (risperidone) extended-release injectable suspension for subcutaneous use.

In June 2022, Pfizer Inc. declared the presentation of a New Drug Application (NDA) for approval of PAXLOVID™ (tablets and ritonavir tablets) to the U.S. FDA for patients who are at severe risk of illness from COVID-19.

In July 2020, Mylan N.V. announced the commercial launch of Remdesivir under the brand name DESREM in India to fulfill the urgent demand amid the coronavirus pandemic.

Key Questions Answered in This Report

  • 1. What was the size of the global generic drugs market in 2023?
  • 2. What is the expected growth rate of the global generic drugs market during 2024-2032?
  • 3. What are the key factors driving the global generic drugs market?
  • 4. What has been the impact of COVID-19 on the global generic drugs market?
  • 5. What is the breakup of the global generic drugs market based on the therapy area?
  • 6. What is the breakup of the global generic drugs market based on the drug delivery?
  • 7. What is the breakup of the global generic drugs market based on the distribution channel?
  • 8. What are the key regions in the global generic drugs market?
  • 9. Who are the key players/companies in the global generic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Generic Drugs Industry

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Country
  • 5.5 Market Breakup by Therapy Area
  • 5.6 Market Breakup by Drug Delivery
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Forecast
  • 5.9 SWOT Analysis
    • 5.9.1 Overview
    • 5.9.2 Strengths
    • 5.9.3 Weaknesses
    • 5.9.4 Opportunities
    • 5.9.5 Threats
  • 5.10 Value Chain Analysis
    • 5.10.1 Research and Development
    • 5.10.2 Manufacturing
    • 5.10.3 Marketing and Distribution
  • 5.11 Porter's Five Forces Analysis
    • 5.11.1 Overview
    • 5.11.2 Bargaining Power of Buyers
    • 5.11.3 Bargaining Power of Suppliers
    • 5.11.4 Degree of Competition
    • 5.11.5 Threat of New Entrants
    • 5.11.6 Threat of Substitutes
  • 5.12 Regulations in the Generic Industry
  • 5.13 Key Market Drivers and Success Factors

6 Performance of Key Countries

  • 6.1 United States
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 China
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Brazil
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Germany
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 France
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 India
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 United Kingdom
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Japan
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast
  • 6.9 Canada
    • 6.9.1 Market Trends
    • 6.9.2 Market Forecast
  • 6.10 Italy
    • 6.10.1 Market Trends
    • 6.10.2 Market Forecast
  • 6.11 Others
    • 6.11.1 Market Trends
    • 6.11.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Central Nervous System
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiovascular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dermatology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Genitourinary/Hormonal
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Respiratory
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Rheumatology
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Diabetes
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Oncology
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast
  • 7.9 Others
    • 7.9.1 Market Trends
    • 7.9.2 Market Forecast

8 Market Breakup by Drug Delivery

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectables
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Dermal/Topical
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Inhalers
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Retail Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Hospital Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Market Breakup by Key Players
  • 10.3 Key Player Profiles
    • 10.3.1 Teva Pharmaceuticals Industries Ltd.
    • 10.3.2 Mylan N.V.
    • 10.3.3 Novartis AG
    • 10.3.4 Pfizer Inc.
    • 10.3.5 Sun Pharmaceutical Industries Ltd.
    • 10.3.6 Fresenius SE & Co.
    • 10.3.7 Lupin Limited
    • 10.3.8 Endo Pharmaceuticals Inc.
    • 10.3.9 Aurobindo Pharma Limited
    • 10.3.10 Aspen Pharmacare Holdings Limited

11 Generic Drugs Manufacturing Process

  • 11.1 Product Overview
  • 11.2 Detailed Process Flow (Tablets)
  • 11.3 Detailed Process Flow (Injectable)
  • 11.4 Various Types of Unit Operations Involved
  • 11.5 Mass Balance and Raw Material Requirements

12 Project Details, Requirements and Costs Involved

  • 12.1 Land Requirements and Expenditures
  • 12.2 Construction Requirements and Expenditures
  • 12.3 Plant Machinery
  • 12.4 Machinery Pictures
  • 12.5 Raw Material Requirements and Expenditures
  • 12.6 Packaging Requirements and Expenditures
  • 12.7 Transportation Requirements and Expenditures
  • 12.8 Utility Requirements and Expenditures
  • 12.9 Manpower Requirements and Expenditures
  • 12.10 Other Capital Investments

13 Loans and Financial Assistance

14 Project Economics

  • 14.1 Capital Cost of the Project
  • 14.2 Techno-Economic Parameters
  • 14.3 Product Pricing and Margins Across Various Levels of the Supply Chain
  • 14.4 Taxation and Depreciation
  • 14.5 Income Projections
  • 14.6 Expenditure Projections
  • 14.7 Financial Analysis
  • 14.8 Profit Analysis

List of Figure

  • Figure 1: Global: Generic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Generic Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Generic Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Generic Drugs Market: Breakup by Country (in %), 2023
  • Figure 5: Global: Generic Drugs Market: Breakup by Therapy Area (in %), 2023
  • Figure 6: Global: Generic Drugs Market: Breakup by Drug Delivery (in %), 2023
  • Figure 7: Global: Generic Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 8: Global: Generic Drugs Industry: SWOT Analysis
  • Figure 9: Global: Generic Drugs Industry: Value Chain Analysis
  • Figure 10: Global: Generic Drugs Industry: Porter's Five Forces Analysis
  • Figure 11: USA: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 12: USA: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 13: China: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 14: China: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 15: Brazil: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 16: Brazil: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 17: Germany: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 18: Germany: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 19: France: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 20: France: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 21: India: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 22: India: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 23: United Kingdom: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 24: United Kingdom: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 25: Japan: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 26: Japan: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 27: Canada: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 28: Canada: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 29: Italy: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 30: Italy: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 31: Others: Generic Drugs Market (in Million US$), 2018 & 2023
  • Figure 32: Others: Generic Drugs Market Forecast (in Million US$), 2024-2032
  • Figure 33: Global: Generic Drugs Market: Oral (in Million US$), 2018 & 2023
  • Figure 34: Global: Generic Drugs Market Forecast: Oral (in Million US$), 2024-2032
  • Figure 35: Global: Generic Drugs Market: Injectables (in Million US$), 2018 & 2023
  • Figure 36: Global: Generic Drugs Market Forecast: Injectables (in Million US$), 2024-2032
  • Figure 37: Global: Generic Drugs Market: Dermal/Topical (in Million US$), 2018 & 2023
  • Figure 38: Global: Generic Drugs Market Forecast: Dermal/Topical (in Million US$), 2024-2032
  • Figure 39: Global: Generic Drugs Market: Inhalers (in Million US$), 2018 & 2023
  • Figure 40: Global: Generic Drugs Market Forecast: Inhalers (in Million US$), 2024-2032
  • Figure 41: Global: Generic Drugs Market: Central Nervous System (in Million US$), 2018 & 2023
  • Figure 42: Global: Generic Drugs Market Forecast: Central Nervous System (in Million US$), 2024-2032
  • Figure 43: Global: Generic Drugs Market: Cardiovascular (in Million US$), 2018 & 2023
  • Figure 44: Global: Generic Drugs Market Forecast: Cardiovascular (in Million US$), 2024-2032
  • Figure 45: Global: Generic Drugs Market: Dermatology (in Million US$), 2018 & 2023
  • Figure 46: Global: Generic Drugs Market Forecast: Dermatology (in Million US$), 2024-2032
  • Figure 47: Global: Generic Drugs Market: Genitourinary/Hormonal (in Million US$), 2018 & 2023
  • Figure 48: Global: Generic Drugs Market Forecast: Genitourinary/Hormonal (in Million US$), 2024-2032
  • Figure 49: Global: Generic Drugs Market: Respiratory (in Million US$), 2018 & 2023
  • Figure 50: Global: Generic Drugs Market Forecast: Respiratory (in Million US$), 2024-2032
  • Figure 51: Global: Generic Drugs Market: Rheumatology (in Million US$), 2018 & 2023
  • Figure 52: Global: Generic Drugs Market Forecast: Rheumatology (in Million US$), 2024-2032
  • Figure 53: Global: Generic Drugs Market: Diabetes (in Million US$), 2018 & 2023
  • Figure 54: Global: Generic Drugs Market Forecast: Diabetes (in Million US$), 2024-2032
  • Figure 55: Global: Generic Drugs Market: Oncology (in Million US$), 2018 & 2023
  • Figure 56: Global: Generic Drugs Market Forecast: Oncology (in Million US$), 2024-2032
  • Figure 57: Global: Generic Drugs Market: Other Therapy Areas (in Million US$), 2018 & 2023
  • Figure 58: Global: Generic Drugs Market Forecast: Other Therapy Areas (in Million US$), 2024-2032
  • Figure 59: Global: Generic Drugs Market: Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 60: Global: Generic Drugs Market Forecast: Retail Pharmacies (in Million US$), 2024-2032
  • Figure 61: Global: Generic Drugs Market: Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 62: Global: Generic Drugs Market Forecast: Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 63: Generic Drugs Industry: Profit Margins at Various Levels of the Supply Chain
  • Figure 64: Generic Drugs Manufacturing: Production Cost Breakup (in %)
  • Figure 65: Generic Drugs Manufacturing: Detailed Process Flow
  • Figure 66: Generic Drugs Manufacturing Process: Conversion Rate of Feedstocks
  • Figure 67: Generic Drugs Manufacturing: Proposed Plant Layout
  • Figure 68: Generic Drugs Manufacturing Plant: Breakup of Capital Costs (in %)

List of Table

  • Table 1: Global: Generic Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Generic Drugs Market Forecast: Breakup by Country (in Million US$), 2024-2032
  • Table 3: Global: Generic Drugs Market Forecast: Breakup by Therapy Area (in Million US$), 2024-2032
  • Table 4: Global: Generic Drugs Market Forecast: Breakup by Drug Delivery (in Million US$), 2024-2032
  • Table 5: Global: Generic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Generic Drugs Market: Competitive Structure
  • Table 7: Generic Drugs Market: Key Players
  • Table 8: Generic Drugs Manufacturing Plant: Costs Related to Land and Site Development (in US$)
  • Table 9: Generic Drugs Manufacturing Plant: Costs Related to Civil Works (in US$)
  • Table 10: Generic Drugs Manufacturing Plant: Costs Related to Machinery Unit (in US$)
  • Table 11: Generic Drugs Manufacturing Plant: Raw Material Requirements
  • Table 12: Generic Drugs Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
  • Table 13: Generic Drugs Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
  • Table 14: Details of Financial Assistance Offered by Financial Institutions
  • Table 15: Generic Drugs Manufacturing Plant: Capital Costs (in US$)
  • Table 16: Generic Drugs Manufacturing Plant: Techno-Economic Parameters
  • Table 17: Generic Drugs Manufacturing Plant: Taxation and Depreciation (in US$)
  • Table 18: Generic Drugs Manufacturing Plant: Income Projections (in US$)
  • Table 19: Generic Drugs Manufacturing Plant: Expenditure Projections (in US$)
  • Table 20: Generic Drugs Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability (in US$)
  • Table 21: Generic Drugs Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability (in US$)
  • Table 22: Generic Drugs Manufacturing Plant: Profit and Loss Account (in US$)